Impotence disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: IMP005 MIFTS: 56	Impotence Categories: Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence ¹¹ ⁵³ ¹⁴

Erectile Dysfunction ¹¹ ²⁸ ⁵³ ⁴¹ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Erectile Dysfunction Adverse Event ⁷¹

Sexual Impotence ¹¹

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:1875

NCIt ⁴⁹ C3133

EFO ¹⁶ EFO_0004234

UMLS ⁷¹ C0242350 C1961100

Sources

Summaries for Impotence

MedlinePlus: ⁴¹ Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and prolactinoma, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Impotence is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Signal Transduction and MIF Mediated Glucocorticoid Regulation. The drugs Nebivolol and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, prostate and spinal cord, and related phenotypes are homeostasis/metabolism and normal

Disease Ontology: ¹¹ A sexual dysfunction that is characterized by persistent or recurrent inability to achieve or to maintain an erection during sexual activity.

Wikipedia: ⁷⁵ Erectile dysfunction (ED), also called impotence, is the type of sexual dysfunction in which the penis... more...

Sources

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 832)

#	Related Disease	Score	Top Affiliating Genes
1	vasculogenic impotence	32.9	PDE5A ACE
2	prolactinoma	31.9	VIP TGFB1 SHBG PRL
3	conn's syndrome	31.9	PRL KNG1 EDN1 CYP3A4 ACE
4	lipid metabolism disorder	31.5	SHBG PDE5A NOS3 EDN1 CYP3A4 ACE
5	arteries, anomalies of	31.5	VEGFA NOS3 EDN1 ACE
6	apnea, obstructive sleep	31.5	VEGFA NOS3 EDN1 ACE
7	priapism	31.4	PDE5A NOS3 NOS2 EDN1
8	nonarteritic anterior ischemic optic neuropathy	31.3	VEGFA PDE5A NOS3 EDN1
9	hyperprolactinemia	31.2	VIP SHBG PRL
10	peyronie's disease	31.2	TGFB1 PDE5A NOS3 NOS1
11	optic nerve disease	31.2	VEGFA PDE5A EDN1 ACE
12	cardiovascular system disease	31.1	SHBG PDE5A NOS3 NOS2 KNG1 EDNRA
13	lipoprotein quantitative trait locus	31.1	VEGFA PDE5A NOS3 NOS2 KNG1 EDN1
14	type 2 diabetes mellitus	31.1	VEGFA TGFB1 SHBG PRL PDE5A NOS3
15	peripheral artery disease	30.9	VEGFA NOS3 ACE
16	microvascular complications of diabetes 5	30.9	VEGFA NOS3 NOS2 ACE
17	stroke, ischemic	30.8	VEGFA NOS3 EDNRA ANGPT1 ACE
18	hypogonadism	30.7	SHBG PRL PDE5A KLK3
19	heart disease	30.7	VEGFA TGFB1 PDE5A NOS3 NOS2 NOS1
20	bladder neck obstruction	30.7	PDE5A KLK3 ACE
21	systemic scleroderma	30.7	VEGFA EDNRA EDN1 ACE
22	peripheral vascular disease	30.6	VEGFA PDE5A NOS3 EDN1 ACE
23	vascular disease	30.6	VEGFA TGFB1 PDE5A NOS3 NOS2 KNG1
24	hypoactive sexual desire disorder	30.6	SHBG PRL PDE5A
25	varicocele	30.6	VEGFA SHBG PRL NOS3
26	arteriosclerosis	30.5	SHBG EDNRA EDN1 ACE
27	peyronie disease	30.5	TGFB1 PDE5A NOS2
28	orthostatic intolerance	30.5	NOS3 NOS2 ACE
29	congestive heart failure	30.5	VEGFA PDE5A KNG1 EDNRA EDN1 ANGPT1
30	peripheral nervous system disease	30.5	VIP VEGFA KNG1 EDN1 CYP3A4 ACE
31	microvascular complications of diabetes 1	30.5	VEGFA EDN1 ANGPT1
32	alopecia, androgenetic, 1	30.5	SRD5A1 SHBG
33	insulin-like growth factor i	30.5	VEGFA TGFB1 SHBG PRL
34	androgenic alopecia	30.5	VEGFA SRD5A1 SHBG PRL
35	systolic heart failure	30.4	PDE5A EDN1 ACE
36	nonobstructive coronary artery disease	30.4	NOS3 EDN1 ACE
37	exanthem	30.4	VEGFA CYP3A4 ACE
38	pulmonary disease, chronic obstructive	30.4	TGFB1 PDE5A PDE4A ACE
39	buerger disease	30.4	VEGFA NOS3 EDN1
40	diabetic angiopathy	30.4	VEGFA NOS3 EDN1
41	lung disease	30.3	VEGFA TGFB1 PDE4A EDN1 ACE
42	bowel dysfunction	30.3	VIP CYP3A4 ACE
43	skin disease	30.3	VIP VEGFA SRD5A1 PDE4A KNG1 CYP3A4
44	portal hypertension	30.2	NOS3 EDNRA EDN1 ACE
45	angina pectoris	30.2	NOS3 KNG1 EDN1 ACE
46	aortic aneurysm	30.2	VEGFA TGFB1 NOS3 ACE
47	sexual health disorder	30.2	SHBG PRL PDE5A
48	carotid stenosis	30.2	VEGFA NOS3 ACE
49	ischemia	30.2	VEGFA PDE5A NOS3 NOS2 NOS1 KNG1
50	prostatitis	30.2	TGFB1 PRL PDE5A KLK3

Graphical network of the top 20 diseases related to Impotence:

Sources

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:

tremor; angina pectoris; equilibration disorder; pelvic pain; symptom/complaint potency (excluding p07 p08); inability to maintain erection; unable to perform sex

GenomeRNAi Phenotypes related to Impotence according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	ACE ANGPT1 CYP3A4 EDN1 EDNRA KCNMA1
2	no effect	GR00402-S-2	10.2	ACE CYP3A4 EDN1 KCNMA1 KLK3 KNG1

MGI Mouse Phenotypes related to Impotence:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.21	ACE ANGPT1 CYP3A4 EDN1 EDNRA KCNMA1
2	normal	MP:0002873	10.18	CYP3A4 EDN1 EDNRA KLK3 NOS1 NOS3
3	renal/urinary system	MP:0005367	10.16	ACE ANGPT1 EDN1 EDNRA KCNMA1 NOS1
4	muscle	MP:0005369	10.13	ANGPT1 EDN1 EDNRA KCNMA1 KLK3 NOS1
5	endocrine/exocrine gland	MP:0005379	10.06	ACE EDN1 EDNRA NOS1 NOS2 NOS3
6	liver/biliary system	MP:0005370	10.01	ACE NOS1 NOS2 NOS3 PDE5A PRL
7	cardiovascular system	MP:0005385	9.97	ACE ANGPT1 EDN1 EDNRA KCNMA1 KLK3
8	digestive/alimentary	MP:0005381	9.86	EDN1 EDNRA KCNMA1 NOS1 NOS2 NOS3
9	immune system	MP:0005387	9.77	ACE ANGPT1 EDNRA KCNMA1 NOS1 NOS2
10	reproductive system	MP:0005389	9.36	ACE KCNMA1 NOS1 NOS2 NOS3 PDE3A

Sources

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nebivolol

Approved, Investigational

Phase 4

152520-56-4, 99200-09-6, 118457-14-0

71301

Selegiline

Approved, Investigational, Vet_approved

Phase 4

14611-51-9, 14611-52-0

5195 26757

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Allantoin

Approved

Phase 4

97-59-6

204

Curcumin

Approved, Investigational

Phase 4

458-37-7, 84765-67-3

969516

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Yohimbine

Approved, Investigational, Vet_approved

Phase 4

146-48-5

8969

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Testosterone

Approved, Investigational

Phase 4

58-22-0

5408 6013

Methyltestosterone

Approved

Phase 4

58-18-4

6010

Testosterone undecanoate

Approved, Investigational

Phase 4

5949-44-0

21873174 65157

Testosterone enanthate

Approved

Phase 4

315-37-7

9416

Arginine

Approved, Investigational, Nutraceutical

Phase 4

74-79-3

6322

N,N-dimethylarginine

Experimental

Phase 4

30315-93-6

123831

Protective Agents

Phase 4

Neuroprotective Agents

Phase 4

Antiparkinson Agents

Phase 4

Monoamine Oxidase Inhibitors

Phase 4

Vardenafil Dihydrochloride

Phase 4

Antihypertensive Agents

Phase 4

Angiotensin Receptor Antagonists

Phase 4

Neurotransmitter Agents

Phase 4

Adrenergic Agents

Phase 4

Adrenergic Antagonists

Phase 4

Adrenergic alpha-Antagonists

Phase 4

Calcium, Dietary

Phase 4

Anticoagulants

Phase 4

Chelating Agents

Phase 4

Calcineurin Inhibitors

Phase 4

Insulin, Globin Zinc

Phase 4

Insulin

Phase 4

Hypoglycemic Agents

Phase 4

Yohimbe

Phase 4

Mydriatics

Phase 4

Angiotensinogen

Phase 4

16133225

Angiotensin II Type 1 Receptor Blockers

Phase 4

Giapreza

Phase 4

Anesthetics

Phase 4

Anesthetics, Local

Phase 4

Phosphodiesterase 5 Inhibitors

Phase 4

Anabolic Agents

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Androgens

Phase 4

Interventional clinical trials:

(show top 50) (show all 534)

#	Name	Status	NCT ID	Phase	Drugs
1	Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction	Unknown status	NCT02943356	Phase 4	Tadalafil
2	Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction.	Unknown status	NCT01885988	Phase 4	Nebivolol;Sugar Pill
3	Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV.	Unknown status	NCT00555087	Phase 4	Testosterone Undecanoate and/or PDE-5
4	a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency)	Unknown status	NCT03290313	Phase 4	shu gan yi yang capsule;shu gan yi yang capsule simulation agent
5	Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury	Unknown status	NCT00725790	Phase 4	Vardenafil;Placebo
6	Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial	Unknown status	NCT03169582	Phase 4	Avanafil;Sildenafil
7	A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy	Unknown status	NCT03142542	Phase 4	ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
8	Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy	Unknown status	NCT00906269	Phase 4	Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
9	Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis	Unknown status	NCT02344823	Phase 4	Vardenafil;Placebo intake once daily
10	An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.	Unknown status	NCT02225548	Phase 4	Selegiline;Tadalafil
11	The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction	Unknown status	NCT00313898	Phase 4	sildenafil (viagra)
12	A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment	Unknown status	NCT01364701	Phase 4	Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
13	A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment	Unknown status	NCT00498680	Phase 4	Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
14	Assessment of Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction	Completed	NCT05446493	Phase 4	Tadalafil 5mg
15	A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors.	Completed	NCT00668096	Phase 4	Levitra (Vardenafil, BAY38-9456);Placebo
16	A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction	Completed	NCT00663130	Phase 4	Levitra (Vardenafil, BAY38-9456);Tadalafil
17	An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes.	Completed	NCT00664833	Phase 4
18	An International, Multicentre, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfunction Treated With Sildenafil Citrate	Completed	NCT00648596	Phase 4	sildenafil;placebo
19	A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes	Completed	NCT00645268	Phase 4	sildenafil;placebo
20	A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction	Completed	NCT00654082	Phase 4	sildenafil;placebo
21	Evaluation of Systemic and Penile Microvascular Endothelial Function and Arterial Pressure After Chronic Administration of Sildenafil in Hypertensive Men With Erectile Dysfunction	Completed	NCT02620995	Phase 4	sildenafil citrate
22	Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy	Completed	NCT00422578	Phase 4	tadalafil
23	Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction	Completed	NCT00421460	Phase 4	Testosterone Undecanoate,1000mg
24	A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II	Completed	NCT00377793	Phase 4	Levitra (Vardenafil, BAY38-9456);Placebo
25	A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction.	Completed	NCT00665340	Phase 4	Placebo;Levitra (Vardenafil, BAY38-9456)
26	A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction	Completed	NCT00660998	Phase 4	Levitra (Vardenafil, BAY38-9456);Placebo
27	A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction	Completed	NCT01698684	Phase 4	Placebo;Avanafil 100 mg;Avanafil 200 mg
28	Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction.	Completed	NCT00665054	Phase 4	Levitra (Vardenafil, BAY38-9456);Placebo
29	A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra (Sildenafil Citrate) And Cialis (Tadalafil)	Completed	NCT00644956	Phase 4	tadalafil;sildenafil
30	Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction?	Completed	NCT00547599	Phase 4	tadalafil
31	Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction	Completed	NCT00681772	Phase 4	Levitra (Vardenafil, BAY38-9456)
32	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia.	Completed	NCT00663845	Phase 4	Levitra (Vardenafil, BAY38-9456);Placebo
33	Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals	Completed	NCT00662441	Phase 4	Levitra (Vardenafil, BAY38-9456)
34	Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC)	Completed	NCT00738400	Phase 4	Vardenafil (Levitra, BAY38-9456);Placebo
35	Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia	Completed	NCT00668135	Phase 4	Vardenafil (Levitra, BAY38-9456);Placebo
36	Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Flexible, Titration Dose Administered on an As Needed Basis (PRN) to Evaluate the Efficacy and the Safety of Sildenafil for the Treatment of Erectile Dysfunction in Male Patients on Hemodialysis	Completed	NCT00654017	Phase 4	placebo;sildenafil
37	A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States	Completed	NCT00644631	Phase 4	sildenafil;placebo
38	Oral Administration of L-Arginine in Patients With Erectile Dysfunction	Completed	NCT00777075	Phase 4	L-arginine;Placebo
39	Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference	Completed	NCT00547352	Phase 4	tadalafil;sildenafil
40	A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction	Completed	NCT00547092	Phase 4	tadalafil;sildenafil
41	Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction	Completed	NCT00512707	Phase 4	Sildenafil citrate (open label);Testosterone gel
42	A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico.	Completed	NCT00468650	Phase 4	sildenafil citrate
43	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia	Completed	NCT00379756	Phase 4	LEVITRA (vardenafil);placebo
44	Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II	Completed	NCT00143260	Phase 4	Viagra (Sildenafil Citrate) 100 mg
45	A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States	Completed	NCT00143221	Phase 4	Viagra;Placebo
46	Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil	Completed	NCT00159848	Phase 4
47	An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)	Completed	NCT00151463	Phase 4	sildenafil citrate
48	Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors	Completed	NCT01122264	Phase 4	Tadalafil;Sildenafil Citrate
49	A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate	Completed	NCT00159900	Phase 4	Sildenafil Citrate
50	A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED)	Completed	NCT00159809	Phase 4	Viagra (Sildenafil citrate)

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Ginseng Preparation

Methyltestosterone

METHYLTESTOSTERONE PWDR

Papaverine

Papaverine Hydrochloride

yohimbine

Yohimbine hydrochloride

Sources

Genetic Tests for Impotence

Genetic tests related to Impotence:

#	Genetic test	Affiliating Genes
1	Erectile Dysfunction ²⁸

Sources

Anatomical Context for Impotence

Organs/tissues related to Impotence:

MalaCards : Bone Marrow, Prostate, Spinal Cord, Smooth Muscle, Kidney, Endothelial, Bone

Sources

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 22475)

#	Title	Authors	PMID	Year
1	Analyzing the Clinical Efficacy of a Type 5 Phosphodiesterase Inhibitor Combined With Ziyin Baihuo Granules in the Treatment of Erectile Dysfunction. ⁶² ⁴¹	Wang R...Zhang WX	36444907	2022
2	Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. ⁶² ⁴¹	Chen Q...Tang S	36419863	2022
3	Mental and Sexual Health of Men in Times of COVID-19 Lockdown. ⁴¹	Szuster E...Kalka D	36430046	2022
4	Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. ⁵³ ⁶²	Clewell A...Schauss AG	20043970	2010
5	Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. ⁵³ ⁶²	Dorsey P...Hellstrom WJ	20402554	2010
6	T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. ⁵³ ⁶²	Sinici I...Hayran M	19800665	2010
7	Adaptive spaced education improves learning efficiency: a randomized controlled trial. ⁵³ ⁶²	Kerfoot BP	20022032	2010
8	Pharmacotherapy for erectile dysfunction. ⁵³ ⁶²	Eardley I...Lee SW	20092451	2010
9	Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. ⁵³ ⁶²	Garcia-Cardoso J...Lopez-Farre AJ	19907424	2010
10	Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. ⁵³ ⁶²	Lombardi G...Del Popolo G	19686427	2009
11	Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. ⁵³ ⁶²	Qaseem A...Clinical Efficacy Assessment Subcommittee of the American College of Physicians	19884625	2009
12	[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. ⁵³ ⁶²	Rui WB...Chen XW	20112748	2009
13	Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? ⁵³ ⁶²	Savas M...Verit A	19234311	2009
14	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. ⁵³ ⁶²	Fusco F...Italian EDOS Study Group	19701217	2009
15	Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. ⁵³ ⁶²	Meluzin J...Sramkova T	19466514	2009
16	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. ⁵³ ⁶²	Al-Ameri H...Kloner RA	19387454	2009
17	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. ⁵³ ⁶²	Kumar P...Tang WH	19377497	2009
18	Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. ⁵³ ⁶²	Lombardi G...Del Popolo G	19210710	2009
19	EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. ⁵³ ⁶²	Okuyucu EE...Yilmazer S	19036180	2009
20	In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. ⁵³ ⁶²	Kaminetsky JC...Stecher VJ	19143914	2009
21	[Psychosis and sexuality]. ⁵³ ⁶²	Dallon C...Abraham G	19365914	2009
22	Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. ⁵³ ⁶²	Liguori G...Belgrano E	19138360	2009
23	Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. ⁵³ ⁶²	Ko IG...Kim CJ	19010346	2009
24	Online spaced education to teach urology to medical students: a multi-institutional randomized trial. ⁵³ ⁶²	Kerfoot BP...Brotschi E	18614145	2009
25	PDE5 inhibitors in non-urological conditions. ⁵³ ⁶²	Vlachopoulos C...Stefanadis C	19860698	2009
26	Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. ⁵³ ⁶²	Rosenberg MT...McCallum SW	19125990	2009
27	Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. ⁵³ ⁶²	Fugl-Meyer A...Stothard D	19170852	2009
28	[Tadalafil for erectile dysfunction: excellent safety and tolerance]. ⁵³ ⁶²	Bai WJ	19288756	2009
29	Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. ⁵³ ⁶²	Kim YH...Choi NS	18976905	2008
30	New treatments for localized prostate cancer. ⁵³ ⁶²	Marberger M...Abenhaim LL	19095127	2008
31	5-alpha reductase inhibitors and erectile dysfunction: the connection. ⁵³ ⁶²	Erdemir F...Hellstrom WJ	19090946	2008
32	The role of combination medical therapy in benign prostatic hyperplasia. ⁵³ ⁶²	Greco KA...McVary KT	19002123	2008
33	Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. ⁵³ ⁶²	Thurtell MJ...Tomsak RL	18528398	2008
34	Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. ⁵³ ⁶²	Korkes F...Perez MD	18331258	2008
35	Pulmonary embolism after tadalafil ingestion. ⁵³ ⁶²	Chen HC...Wang CY	18548330	2008
36	The effect of 5 alpha-reductase inhibitors on erectile function. ⁵³ ⁶²	Canguven O...Burnett AL	18421068	2008
37	[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. ⁵³ ⁶²	Deng SM	18998474	2008
38	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. ⁵³ ⁶²	Dell'Agli M...Bosisio E	18778098	2008
39	Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. ⁵³ ⁶²	Munger MA...Baker DL	18674473	2008
40	Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. ⁵³ ⁶²	McCarthy HO...Hirst DG	18644193	2008
41	Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. ⁵³ ⁶²	Zumbe J...Ulbrich E	18395326	2008
42	Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. ⁵³ ⁶²	Kerfoot BP	18423715	2008
43	A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. ⁵³ ⁶²	Stief CG...Ulbrich E	18281145	2008
44	[Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction]. ⁵³ ⁶²	Chen WG...Yan CY	18572862	2008
45	Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. ⁵³ ⁶²	Tan HM...Yip WC	18385912	2008
46	[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]. ⁵³ ⁶²	Zhu XW...Li FY	18572866	2008
47	The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. ⁵³ ⁶²	Brock G...Ward R	18304285	2008
48	Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. ⁵³ ⁶²	Pimentel H...Niederberger C	18075506	2008
49	Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. ⁵³ ⁶²	Tamagno G...Beckers A	18082643	2008
50	Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. ⁵³ ⁶²	Ljunggren C...Stroberg P	18086159	2008

Sources

Genes for Impotence

Genes related to Impotence (0 elite genes):

(show all 39)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PDE5A	Phosphodiesterase 5A	Protein Coding	37.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	10541153 18778098 12789393 (more) 17017938 12192104 17253475 17948826 17076943 18674473 20092451 15183543 18572866 16465185 15941818 19234311 16760637 16913726 10753463 17888073 17625575 16985897 18528398 16212722 17655683 16901064 19884625 9598563 10078541 10859452 12494279 15224136 16759100 16780568 17947271 20043970 19686427 20112748 19036180 18395326 18385912 18086159 18304285 17942972 18075506 17969789 17943864 17307372 17034932 17321461 16387566 16480739 16884667 15102574 14693299 12625846 10078540 10078538 10078537 8858389 19125990 19210710 16979814 17100936 16956354 16236060 16839323 16985983 16422974 16755146 16422803 16387564 16281846 14622499 12437503 12414329 12209148 9916601 20402554 19860698 19377497 19138360 18998474 18673225 18548330 17393785 17471999 17233781 16422913 16387565 16247643 15850242 15648556 15175637 15242361 15224127 19701217 19170852 19387454 19010346 18331258 19288756 18976905 18281145 15766322
2	NOS1	Nitric Oxide Synthase 1	Protein Coding	33.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Drugs & Compounds (show sections)	7588327 10630682 9284206 (more) 9631946 8562693
3	PRL	Prolactin	Protein Coding	30.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9334596 8801788 17213792 (more) 15794243 16728967 9934944 12771765 15230214 15277002 16985734 11525317 16466670 15206663 17125484 17724876 8077999 12522680 19365914 1352308 7555478 8800626 17040261 18082643 8845563 8683729 7824423 11111867
4	VIP	Vasoactive Intestinal Peptide	Protein Coding	27.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Drugs & Compounds (show sections)	1522236 8981173 14617572 (more) 7601214 2405186 11678758
5	SRD5A1	Steroid 5 Alpha-Reductase 1	Protein Coding	25.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	1841751 15371854 18421068 (more) 16110128 19002123 17166332 19090946 17265598 16507052 18163946
6	SHBG	Sex Hormone Binding Globulin	Protein Coding	23.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	8274414 17961146 15794243
7	KLK3	Kallikrein Related Peptidase 3	Protein Coding	23.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18423715 9334599 18001791 (more) 12399540 15711315 15852361 15201795 19095127 17137429 16422891 17030406 12771765 11421528 20022032 18614145 15201794 18217535 11752011 15491704 8795650 11121994 11325208
8	NOS3	Nitric Oxide Synthase 3	Protein Coding	23.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	10553806 19466514 16871271 (more) 16085713 18572862 16528291 19800665 15292102 14522830 15711333 16409219 9631946 17457350 19907424
9	KNG1	Kininogen 1	Protein Coding	19.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
10	EDN1	Endothelin 1	Protein Coding	17.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	9334598 17222652 16225532 (more) 11550788 17611982 7752383 11760787 7658593
11	NOS2	Nitric Oxide Synthase 2	Protein Coding	17.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	9096878 11781741 16507050 (more) 9631946 12879114 18644193 16554854 12789386 16378509
12	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	16.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	19143914 16282844 11879258
13	PDE3A	Phosphodiesterase 3A	Protein Coding	15.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	10421499 10859452
14	KCNMA1	Potassium Calcium-Activated Channel Subfamily M Alpha 1	Protein Coding	14.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10467518 12879112 15964135 (more) 17402321 17134370 7861546
15	EDNRA	Endothelin Receptor Type A	Protein Coding	14.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Drugs & Compounds (show sections)	11780926
16	PDE4A	Phosphodiesterase 4A	Protein Coding	13.84	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
17	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	13.66	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
18	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	12.87	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
19	ACE	Angiotensin I Converting Enzyme	Protein Coding	12.81	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
20	ANGPT1	Angiopoietin 1	Protein Coding	12.75	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
21	VWF	Von Willebrand Factor	Protein Coding	12.44	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
22	AR	Androgen Receptor	Protein Coding	12.42	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
23	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	12.25	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
24	NPY	Neuropeptide Y	Protein Coding	12.01	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
25	PDE1B	Phosphodiesterase 1B	Protein Coding	11.99	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
26	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	11.95	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
27	NGF	Nerve Growth Factor	Protein Coding	11.95	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
28	GNB3	G Protein Subunit Beta 3	Protein Coding	11.89	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
29	CYP2C9	Cytochrome P450 Family 2 Subfamily C Member 9	Protein Coding	11.74	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
30	ARG2	Arginase 2	Protein Coding	11.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11350073 11370664 12859189
31	PDE11A	Phosphodiesterase 11A	Protein Coding	11.65	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
32	PDE3B	Phosphodiesterase 3B	Protein Coding	11.65	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
33	PDE10A	Phosphodiesterase 10A	Protein Coding	11.6	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
34	PDE4D	Phosphodiesterase 4D	Protein Coding	11.55	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
35	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	11.44	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
36	HTR2C	5-Hydroxytryptamine Receptor 2C	Protein Coding	11.36	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
37	ADRA1D	Adrenoceptor Alpha 1D	Protein Coding	11.34	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
38	PDE4B	Phosphodiesterase 4B	Protein Coding	11.29	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)
39	TAC1	Tachykinin Precursor 1	Protein Coding	11.22	DISEASES inferred ¹⁴ GeneCards inferred via : Drugs & Compounds (show sections)

Sources

Variations for Impotence

Sources

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Sources

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 24)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.56	ANGPT1 EDN1 EDNRA KLK3 KNG1 NOS3
2	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.51	VEGFA TGFB1 NOS3 NOS2 NOS1 EDNRA
3	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.15	VEGFA TGFB1 PDE5A NOS3 NOS2 NOS1
4	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.82	VEGFA PRL NOS3 NOS2 NOS1 ANGPT1
5	Platelet homeostasis ⁶⁶ Show member pathways Elevation of cytosolic Ca2+ levels ⁶⁶ Platelet calcium homeostasis ⁶⁶ Platelet sensitization by LDL ⁶⁶ Prostacyclin signalling through prostacyclin receptor ⁶⁶ Reduction of cytosolic Ca++ levels ⁶⁶	12.14	PDE5A NOS3 NOS2 NOS1 KCNMA1
6	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.83	VEGFA TGFB1 NOS2
7	superpathway of L-citrulline metabolism ⁶¹ Show member pathways citrulline-nitric oxide cycle ⁶¹ Effects of nitric oxide ⁷⁴ L-citrulline biosynthesis ⁶¹ nitric oxide biosynthesis II (mammals) ⁶¹ Nitric oxide metabolism in cystic fibrosis ⁷⁴ urea cycle ⁶¹ Urea cycle ⁶⁶ Urea cycle and associated pathways ⁷⁴ Urea cycle and metabolism of amino groups ⁷⁴	11.77	NOS3 NOS2 NOS1
8	ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE inhibitor pathway ⁷⁴ Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Conversion of angiotensinogen to angiotensin II ⁷⁴ Defective SERPING1 causes hereditary angioedema ⁶⁶ Downregulation of ACE2 by SARS-CoV-2 spike protein ⁷⁴ Kinin-Kallikrein pathway ⁷⁴ Non-classical role of vitamin D ⁷⁴ RAS and bradykinin pathways in COVID-19 ⁷⁴ Renin-angiotensin-aldosterone system (RAAS) ⁷⁴ SARS-CoV-2 and ACE2 receptor: molecular mechanisms ⁷⁴	11.69	TGFB1 NOS3 NOS1 KNG1 CYP3A4 ACE
9	HIF-1-alpha transcription factor network ⁶¹	11.57	VEGFA NOS2 EDN1
10	Mechanisms of CFTR activation by S-nitrosoglutathione (normal and CF) ²² Show member pathways CFTR folding and maturation (norm and CF) ²²	11.52	NOS3 NOS2 NOS1
11	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.48	VEGFA TGFB1 NOS2
12	HIF1Alpha Pathway ⁶⁴	11.47	EDN1 NOS3 VEGFA
13	SHP2 signaling ⁶¹	11.46	ANGPT1 NOS3 VEGFA
14	Phosphodiesterases in neuronal function ⁷⁴	11.45	NOS1 PDE3A PDE4A PDE5A
15	NO/cGMP/PKG mediated neuroprotection ⁷⁴	11.35	PDE3A NOS3 NOS2 NOS1
16	Doxorubicin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶⁰	11.3	NOS3 NOS2 NOS1
17	Photodynamic therapy-induced HIF-1 survival signaling ⁷⁴	11.19	VEGFA NOS2 EDN1 ANGPT1
18	Endothelin pathways ⁷⁴	11.18	NOS3 EDNRA EDN1
19	Doxorubicin Pathway (Cardiomyocyte Cell), Pharmacodynamics ⁶⁰	11.05	NOS3 NOS2 NOS1
20	Prostaglandin synthesis and regulation ⁷⁴ Show member pathways Defective TBXAS1 causes GHDD ⁶⁶ Eicosanoid metabolism via cyclooxygenases (COX) ⁷⁴ Ibuprofen Pathway, Pharmacodynamics ⁶⁰	10.99	PRL NOS3 NOS2 NOS1 EDNRA EDN1
21	Nitric oxide stimulates guanylate cyclase ⁶⁶ Show member pathways cGMP effects ⁶⁶	10.93	PDE5A NOS3 NOS2 NOS1 KCNMA1
22	Quercetin and Nf-kB / AP-1 induced apoptosis ⁷⁴	10.79	VEGFA NOS1
23	NO-dependent CFTR activation (normal and CF) ²²	10.67	PDE5A NOS3 NOS2 NOS1
24	Aspirin and miRNAs ⁷⁴	10.59	VEGFA NOS3

Sources

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	vesicle membrane	GO:0012506	9.1	NOS1 NOS2 NOS3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 46)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	10.38	ACE EDN1 NOS2 TGFB1 VEGFA
2	in utero embryonic development	GO:0001701	10.31	VEGFA NOS3 EDNRA EDN1 ANGPT1
3	response to xenobiotic stimulus	GO:0009410	10.25	TGFB1 SRD5A1 PDE3A EDN1 ACE
4	response to hormone	GO:0009725	10.16	NOS3 NOS2 NOS1
5	response to lipopolysaccharide	GO:0032496	10.16	ACE EDN1 NOS1 NOS2 NOS3
6	cell redox homeostasis	GO:0045454	10.14	NOS3 NOS2 NOS1
7	positive regulation of peptidyl-serine phosphorylation	GO:0033138	10.14	VEGFA TGFB1 NOS1 ANGPT1
8	vasodilation	GO:0042311	10.13	NOS3 NOS1 KNG1
9	regulation of blood pressure	GO:0008217	10.13	NOS3 EDNRA EDN1 ACE
10	blood vessel remodeling	GO:0001974	10.12	NOS3 EDNRA ACE
11	branching involved in blood vessel morphogenesis	GO:0001569	10.09	VEGFA EDNRA EDN1
12	negative regulation of blood pressure	GO:0045776	10.08	NOS3 NOS2 NOS1
13	positive regulation of MAP kinase activity	GO:0043406	10.08	VEGFA TGFB1 PDE5A EDN1
14	nitric oxide biosynthetic process	GO:0006809	10.02	NOS1 NOS2 NOS3
15	axonogenesis involved in innervation	GO:0060385	10	EDNRA EDN1
16	negative regulation of hydrolase activity	GO:0051346	10	NOS3 NOS1
17	vasoconstriction	GO:0042310	10	ACE EDN1 EDNRA
18	regulation of glucose transmembrane transport	GO:0010827	9.99	EDNRA EDN1
19	noradrenergic neuron differentiation	GO:0003357	9.99	EDNRA EDN1
20	cardiac neural crest cell migration involved in outflow tract morphogenesis	GO:0003253	9.99	EDNRA EDN1
21	nitric oxide mediated signal transduction	GO:0007263	9.99	NOS3 NOS2 NOS1
22	cellular response to luteinizing hormone stimulus	GO:0071373	9.98	EDNRA EDN1
23	body fluid secretion	GO:0007589	9.97	VIP EDN1
24	regulation of systemic arterial blood pressure by endothelin	GO:0003100	9.97	NOS3 EDN1
25	peptidyl-cysteine S-nitrosylation	GO:0018119	9.96	NOS1 NOS2
26	sympathetic neuron axon guidance	GO:0097492	9.94	EDNRA EDN1
27	neural crest cell fate commitment	GO:0014034	9.94	EDNRA EDN1
28	regulation of nitric oxide mediated signal transduction	GO:0010749	9.93	PDE5A VEGFA
29	positive regulation of peptidyl-tyrosine autophosphorylation	GO:1900086	9.92	ACE VEGFA
30	positive regulation of guanylate cyclase activity	GO:0031284	9.91	NOS3 NOS2 NOS1
31	positive regulation of blood vessel endothelial cell migration	GO:0043536	9.91	VEGFA TGFB1 NOS3 ANGPT1
32	endothelin receptor signaling pathway involved in heart process	GO:0086101	9.9	EDN1 EDNRA
33	regulation of sodium ion transport	GO:0002028	9.89	TGFB1 NOS3 NOS1
34	cellular response to human chorionic gonadotropin stimulus	GO:0044751	9.88	EDN1 EDNRA
35	positive regulation of oocyte development	GO:0060282	9.87	PDE3A PDE5A
36	meiotic cell cycle process involved in oocyte maturation	GO:1903537	9.86	EDN1 EDNRA
37	response to laminar fluid shear stress	GO:0034616	9.85	TGFB1 ACE
38	response to salt	GO:1902074	9.84	TGFB1 EDN1
39	positive regulation of odontogenesis	GO:0042482	9.8	EDN1 TGFB1
40	positive regulation of vascular permeability	GO:0043117	9.8	VEGFA TGFB1 PDE3A
41	negative regulation of potassium ion transport	GO:0043267	9.8	VIP NOS3 NOS1
42	mononuclear cell proliferation	GO:0032943	9.65	TGFB1 ACE
43	arginine catabolic process	GO:0006527	9.63	NOS3 NOS2 NOS1
44	response to hypoxia	GO:0001666	9.47	VEGFA TGFB1 NOS2 NOS1 KCNMA1 EDNRA
45	cellular biosynthetic process	GO:0044249	9.43	NOS1 NOS2 NOS3
46	blood vessel diameter maintenance	GO:0097746	9.43	NOS3 KNG1 EDN1 ACE

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heme binding	GO:0020037	10.06	NOS3 NOS2 NOS1 CYP3A4
2	NADP binding	GO:0050661	9.88	NOS3 NOS2 NOS1
3	3',5'-cyclic-nucleotide phosphodiesterase activity	GO:0004114	9.8	PDE3A PDE4A PDE5A
4	cadmium ion binding	GO:0046870	9.73	NOS3 NOS1
5	FMN binding	GO:0010181	9.73	NOS3 NOS2 NOS1
6	arginine binding	GO:0034618	9.63	NOS3 NOS2 NOS1
7	phosphoric diester hydrolase activity	GO:0008081	9.54	PDE5A PDE4A PDE3A
8	tetrahydrobiopterin binding	GO:0034617	9.43	NOS3 NOS2 NOS1
9	nitric-oxide synthase activity	GO:0004517	9.1	NOS3 NOS2 NOS1